SY63 - Molecular and metabolic advances in endocrine neoplasia: from pathophysiology to therapeutics?

Symposium Chair(s)

• 

  Karel Pacak, MD,PhD,DSC, FACE (he/him/his)

  Director, Center for Adrenal Endocrine Tumors
  Akeso Holding and Masaryk University, Brno
  Prague 3, Czech Republic

  Disclosure(s): No financial relationships to disclose
• 

  Carmelo Nucera, MD, PhD

  Associate Professor
  BIDMC/Harvard Medical School, Leader: Human Thyroid Cancers Preclinical and Translational Research
  Boston, MA, United States

  Disclosure(s): Vertex: Consultant (), Korean Endocrine Society (honorarium recipient: travel as invited speaker). My disclosures do NOT have any financial relationship to this presentation ()

Metabolic reprogramming plays a critical role in how endocrine tumors evade the immune system, contributing to disease progression and resistance to therapy. This symposium will examine the intersection of metabolism and immune regulation in endocrine cancers,, highlighting advances made these far that have the potential to inform future therapeutic strategies.

Presentations:

• 9:30 AM - 10:00 AM CT

  Chemokine Network in PitNETs: Impact on Tumor Biology and Clinical Outcomes
  

  Symposium Speaker: Pedro Marques, MD, PhD (he/him/his) – Hospital CUF Descobertas
• 10:00 AM - 10:30 AM CT

  Immune-metabolic Deregulation in Thyroid Carcinoma
  

  Symposium Speaker: Romana Netea-Maier, MD,PhD – Radboud University Nijmegen Medical Center